JP2018519296A5 - - Google Patents

Download PDF

Info

Publication number
JP2018519296A5
JP2018519296A5 JP2017566323A JP2017566323A JP2018519296A5 JP 2018519296 A5 JP2018519296 A5 JP 2018519296A5 JP 2017566323 A JP2017566323 A JP 2017566323A JP 2017566323 A JP2017566323 A JP 2017566323A JP 2018519296 A5 JP2018519296 A5 JP 2018519296A5
Authority
JP
Japan
Prior art keywords
domain
protein
unit
polypeptide
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017566323A
Other languages
English (en)
Japanese (ja)
Other versions
JP6840682B2 (ja
JP2018519296A (ja
Filing date
Publication date
Priority claimed from PCT/EP2015/064070 external-priority patent/WO2015197598A2/en
Application filed filed Critical
Priority claimed from PCT/EP2016/064528 external-priority patent/WO2016207273A2/en
Publication of JP2018519296A publication Critical patent/JP2018519296A/ja
Publication of JP2018519296A5 publication Critical patent/JP2018519296A5/ja
Application granted granted Critical
Publication of JP6840682B2 publication Critical patent/JP6840682B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017566323A 2015-06-23 2016-06-23 多重特異的抗原結合タンパク質 Active JP6840682B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2015/064070 WO2015197598A2 (en) 2014-06-27 2015-06-23 Multispecific antigen binding proteins
EPPCT/EP2015/064070 2015-06-23
US201562271491P 2015-12-28 2015-12-28
US62/271,491 2015-12-28
PCT/EP2016/064528 WO2016207273A2 (en) 2015-06-23 2016-06-23 Multispecific antigen binding proteins

Publications (3)

Publication Number Publication Date
JP2018519296A JP2018519296A (ja) 2018-07-19
JP2018519296A5 true JP2018519296A5 (cg-RX-API-DMAC7.html) 2019-06-27
JP6840682B2 JP6840682B2 (ja) 2021-03-10

Family

ID=57584754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566323A Active JP6840682B2 (ja) 2015-06-23 2016-06-23 多重特異的抗原結合タンパク質

Country Status (7)

Country Link
US (1) US20200048345A1 (cg-RX-API-DMAC7.html)
EP (1) EP3313876B1 (cg-RX-API-DMAC7.html)
JP (1) JP6840682B2 (cg-RX-API-DMAC7.html)
AU (1) AU2016284866B2 (cg-RX-API-DMAC7.html)
CA (1) CA2990511A1 (cg-RX-API-DMAC7.html)
DK (1) DK3313876T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016207273A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015279321B2 (en) 2014-06-27 2021-03-04 Innate Pharma, S.A. Multispecific antigen binding proteins
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
AU2016284871B2 (en) 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
JP6944925B2 (ja) 2015-07-24 2021-10-06 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 組織浸潤ｎｋ細胞を検出する方法
AU2017332452B2 (en) * 2016-09-23 2021-01-07 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CA3221995C (en) * 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
WO2018148610A1 (en) * 2017-02-10 2018-08-16 Adimab, Llc Proteins binding psma, nkg2d and cd16
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
SG11201907648XA (en) * 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding gd2, nkg2d and cd16
SG11201907638QA (en) * 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding cd33, nkg2d and cd16
AU2018224319B2 (en) * 2017-02-27 2024-04-04 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting CEA
MX2019014000A (es) * 2017-05-23 2020-07-29 Dragonfly Therapeutics Inc Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor.
BR112019024620A2 (pt) * 2017-05-23 2020-06-23 Dragonfly Therapeutics, Inc. Ligante de proteína nkg2d, cd16 e antígeno associado a tumor
CN111263643A (zh) * 2017-05-23 2020-06-09 蜻蜓疗法股份有限公司 结合nkg2d、cd16和ror1或ror2的蛋白质
AU2018302343B2 (en) * 2017-07-21 2020-11-26 Trianni, Inc. Single chain vh and heavy chain antibodies
CA3072919A1 (en) * 2017-08-23 2019-02-28 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
AU2018371114A1 (en) * 2017-11-21 2020-05-07 Innate Pharma Multispecific antigen binding proteins
KR20200118824A (ko) * 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CN112437672A (zh) * 2018-05-07 2021-03-02 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN112423788A (zh) * 2018-05-16 2021-02-26 蜻蜓疗法股份有限公司 结合nkg2d、cd16和成纤维细胞激活蛋白的蛋白质
CN112384534A (zh) * 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108646A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
US20230365709A1 (en) * 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
JP7623497B2 (ja) 2020-12-31 2025-01-28 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
BR112023025331A2 (pt) * 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258678A1 (en) * 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN113838523A (zh) * 2021-09-17 2021-12-24 深圳太力生物技术有限责任公司 一种抗体蛋白cdr区域氨基酸序列预测方法及系统
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物
CN120322463A (zh) * 2022-09-15 2025-07-15 艾维迪治疗知识产权有限公司 用于nk细胞的肿瘤靶向的多特异性抗原结合蛋白及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
DE10324108B3 (de) 2003-05-21 2005-01-27 Aesculap Ag & Co. Kg Wirbelkörperersatzimplantat
WO2005000086A2 (en) * 2003-06-30 2005-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005115452A2 (en) 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
ES2526811T3 (es) 2005-08-10 2015-01-15 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
EP2021029B1 (en) 2006-05-26 2014-06-11 MacroGenics, Inc. Humanized fc gamma riib-specific antibodies and methods of use thereof
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
CN102369215B (zh) * 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
KR101791430B1 (ko) * 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
EP2982380B1 (en) 2010-03-04 2021-09-01 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
RU2624027C2 (ru) * 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
WO2012088302A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
EP2897980B1 (en) 2012-09-19 2019-11-06 Innate Pharma Kir3dl2 binding agents
WO2014100490A1 (en) * 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
JP6822849B2 (ja) * 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
AU2016284871B2 (en) * 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
JP7623497B2 (ja) * 2020-12-31 2025-01-28 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ

Similar Documents

Publication Publication Date Title
JP2018519296A5 (cg-RX-API-DMAC7.html)
JP2018524326A5 (cg-RX-API-DMAC7.html)
US11180553B2 (en) Chimeric antigen receptor
JP6722189B2 (ja) 単量体Ｆｃドメイン
RU2753882C2 (ru) Трифункциональная антигенсвязывающая молекула
JP2024037778A (ja) 生物学的に関連する直交サイトカイン／受容体対
JP2016516049A5 (cg-RX-API-DMAC7.html)
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
US20160347814A1 (en) Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
RU2022102624A (ru) Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
JP7303391B2 (ja) バイアス型ｉｌ２ムテイン、方法、および組成物
JP2019528077A5 (cg-RX-API-DMAC7.html)
JP2022542543A (ja) 抗ｄｌｌ３キメラ抗原受容体及びその使用
KR20200052373A (ko) 키메라 폴리펩티드 및 그의 용도
JP2019531725A5 (cg-RX-API-DMAC7.html)
JP2015527070A5 (cg-RX-API-DMAC7.html)
JPWO2020047473A5 (cg-RX-API-DMAC7.html)
JP2020529835A (ja) 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法
KR20180057720A (ko) 다가 Fv 항체
CN107405398A (zh) 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
JP2015518479A5 (cg-RX-API-DMAC7.html)
JP2020512820A5 (cg-RX-API-DMAC7.html)
EP4353250A3 (en) Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
JP2019535306A5 (cg-RX-API-DMAC7.html)